LegoChemBio has signed a license agreement with Elthera to develop and commercialise a novel antibody-drug conjugate (ADC) therapy using a monoclonal antibody developed by the Swiss start-up. The licensed asset is a monoclonal antibody with a target expressed in a variety of solid tumors. Elthera will receive an undisclosed upfront payment, milestone payments and royalties on net product sales.
Elthera AG is a Swiss biopharmaceutical company founded in 2016 by experienced Pharma and Biotech executives to develop proprietary, first-in-class oncology drugs using a personalised healthcare approach. Its immunotherapy targets the L1 cell adhesion molecule (L1CAM) that harnesses the patient’s immune system to actively eliminate cancer cells and stop tumour progression. This anti-L1CAM antibody therapy targets several solid tumours, including pancreatic, ovarian, breast, lung, and colorectal cancer.
The newly signed license partnership gives LegoChemBio Biosciences the right to develop and commercialise products incorporating Elthera’s monoclonal antibody. Preclinical results demonstrate the differentiation in efficacy and safety of this first-in-class candidate. Elthera will receive an upfront payment and is eligible to receive progress-dependent development and regulatory milestone payments and cumulative commercial milestone payments. Elthera will additionally receive royalties on net product sales.
“We are very pleased to enter into this license agreement with LegoChemBio, a global ADC company with industry-leading ADC technology,” said Anne Schmidt, CEO of Elthera. “This agreement is the result of a fruitful collaboration with LegoChemBio, demonstrating the outstanding quality and therapeutic potential of our antibody. The combination with LegoChemBio’s ConjuAll technology generates a well-differentiated first-in-class ADC with a wide therapeutic window that has the potential to provide new treatment options for a large number of solid tumours.”
Based in South Korea, LegoChem Biosciences is a clinical-stage biopharmaceutical company focusing on the development of next-generation novel therapeutics utilising its proprietary medicinal drug discovery technology LegoChemistry and ADC platform technology ConjuAll. Since its foundation in 2006, LCB has focused on the research and development of Antibody-Drug-Conjugates (ADCs), anticancer therapeutics, antibiotics and anti-fibrotic based on proprietary platform technologies.
(Press release)
Please login or sign up to comment.
Commenting guidelines